Member Info for CHELSEA7

Ray /Chester,

Only time will tell if Lindy has cracked it, but it certainly has caught the attention of many scientists. That attention more than anything is what is encouraging IMO.

So very true, and it is that that makes me feel confidant.

What we are doing the last three years (under Chiplins direction) is building a sizeable company under the financial restraints of the AIM market. Doubling key staffing personnel over three years is not so easy, and I do think in the Glycans, TCR and Moditope we will build into a viable take over target.

This AGM is very important, and we don"t know why it has been called 4/5 weeks earlier than in previous years, but there just might be a lot to reveal.

Nice posts Inanaco. This is why I am looking forward to the AGM, for updates on the Glycans, TCR and importantly Moditope.

Meanwhilst as we saw again yesterday, large amounts of shares are changing hands, you mentioned sideshows, I think the SBIB 1 trial is possibly the biggest sideshow in town ATM!!!

Jus the 3.6k at 7.30.......but it is blue, lol.

MMs taking 200k+ at 6.865. Just MO think we have a buyer at 7p as yesterdays 2 x 250k trades. Lets see, hope all good.

Violindog, keep on punching. This wretched humidity is making me feel the same ATB

My best wishes too to a true gentleman and wonderful poster. R.I.P

Wassatt Junior, my best to you and your family, only a few posts to go to catch up dad, lol. ATVB X

Well the 300k is a sell, lol......................

Time Trade Price Volume Value
14:50:11 7.00 108,059 7,564 O
14:49:11 7.00 250,000 17.50k O
14:47:29 7.00 250,000 17.50k O
14:45:39 6.8151 300,000 20.45k O
14:05:52 7.10 2,934 208.31 O
08:05:58 7.00 3,500 245.00 O

Up to 120k at 7.1
150k at 7p
200k at 6.8125
over 200k same

Big buy coming?

Suppose what I find confusing is why did we get European Approval but not FDA.

Bermuda, I am trying to work out whether AZ will have the same problem with the FDA. Thet are paying Ichor a yearly fee +, so presumably the problem doesn"t lie with the drug, can we presume from that the problem is centred on the type of drug, i.e. SCIB1?

All sounds a bit contradictory inan. If Scancell have withdrawn the IND application and Ichor never made one, then why can"t Scancell comment on it and surely nobody would be working on it now??

6.80/7.50

MMs will take 215k+ at 7.20, no trade showing, looks like a treeshake to me , just the one trade all day 3.5k sell at 7p

Makes sense to me Bermuda, hence why Scancell have made a point of not commenting on it......it is not their issue, but suffering as a result of it.

Far from last week not being good news, the iND situation felt for a long time there was no solution, just surprised we didn"t decide to start the U.K arm before now.

Not that it helps now, but i just wonder in retrospect given we are new to FDA rules that this situation couldn"t have been foresseen much earlier?

TF. In no way when I use the word "misquote" do i mean you are intentionally trying to mislead. That is something I suppose I could have cleared up a long time ago. As it just happens I read bermudas post carefully because of its content so I knew his issue wasn"t the 25 patients.

Something I would like you to consider is when you disagree with a point, can you give your opinion as to what you think. This to me is a perfect example...........................

""And Ray, C7's comment - ''the U.S. arm IND will have to be re-applied for. Sounds simple to me.'' Fair enough but simple ? I fear not.

Sorry but I just can't go along with last week's news being good. ATB"""

Nobody minds constructive criticism or debate, least of all me, but could you not just say why you think it is not simple?? And if you don"t think last weeks news wasn"t good, why not explain which part wasn"t good. That is what leads to 90% of our crosswords, unnecessary and it takes away the opportunity to debate, and as far as saying you misquoute, no I don"t mean you intentionally do it, but sometimes just taking a small part of a post often leads to the original point being misunderstood. ATB

"""There have been some excellent posts lately and I'm reminded of this - Bermuda 08.55 21/9 - ''I'm not convinced a trial in 25 patients will be enough to persuade big pharma to make a move for SCIB1 and IMO the future of ImmunoBody lies with SCIB2.'' After 9 years of watching SCIB1 progress, that's a bit of a jolt."""

Torquay, once again you have mis quoted somebody elses post. It was not the 25 patients that concerned bermuda, but the possibility of seeing in that many patients sufficient data that improves on Keytruda mono data.

Bermuda, just happens to be in a small group of posters over LSE that I respect hugely, the time you spend cutting and pasting his every word is IMHO disproportionate and you post.......................

"""There have been some excellent posts lately and I'm reminded of this - Bermuda 08.55 21/9 - ''I'm not convinced a trial in 25 patients will be enough to persuade big pharma to make a move for SCIB1 and IMO the future of ImmunoBody lies with SCIB2.'' After 9 years of watching SCIB1 progress, that's a bit of a jolt."""

TF , that is an opinion from a good poster, one very simple way of reading it is he fancies SCIB2 to be more successful than SCIB1 in the trial setting. Really, ""a jolt"" well Keith Flaherty is particularly keen on the study as is Lindy Durrant!! so my best advice is pull yourself together, rather than posting up last week was bad news, when it wasn"t!!!!!!!!!!!!!

Absolutely, was considering that and we will find out eventually, but I do think with the data the SCIB1 mono trial produced, had we of have been using the same delivery system i just can"t imagine what the problem would be?

Anyway we have decided to go ahead with the U.K arm, which quite a few posters did ask why we weren"t just doing that anyway. If our plans are still to trial it under Flaherty as well I am sure very good early data would expedite the IND then, but for now just really pleased we are back into trial, Flaherty will be privy to the same data anyway, and the immediate cash flow has been boosted by the decision too. Just perhaps with two feet out of the American market for now we can fully concentrate on everything in our platforms which will produce data. The focus on the continual use of the word data suggests to me we might just have interest from more than one camp dependant on the data.

As far as not being able to read too much into the early AGM.................Well!!! Pretty easy, it is either significant as Scancell want to get out there updates on all platforms, or it is just to ensure all the BOD are free to be present. I just have a feeling now is the time we could see a push on the PR front, something we have wanted for so long, but the timing seems right now, like never before.

Nearly done with speculating the cause of the delay, lol, but I can"t imagine we would have had such a delay with the FDA if the device was the same as in the SCIB1 mono trial? As it goes, done with speculating now, that is about the only reason that makes any sense to me.

Yep, and listening to the CH interview with Proactive it is becoming very clear we cannot give the reason for delay as it really isn"t our issue. I am just delighted we are back in the clinic in trial, wherever that may be, A very poor post., misleading

I would suggest the normal crowd on ADVFN are making a huge deal about the U.S arm, but that is a misleading post, the trial hasn"t been downgraded in the U.K. just beginning first.

3.5k at 7p sell. Why sell at 7p when it is 7.2?? Doh!!